EDIT - Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline
- Editas Medicine ( NASDAQ: EDIT ) rose 4.2% on a report that the CRISPR gene editing company is in advanced talks for the sale of its preclinical oncology lineup, according to Endpoint News.
- Last month, Editas Medicine was started at neutral at BofA due to competition in gene editing programs.
For further details see:
Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline